Ноотропная терапия в лечение нарушений активности, внимания и поведения у детей

The study objective was to identify clinical efficacy and tolerability of omaroni administered as mono and polytherapy. A total of 104 patients at the age from 6 to 12 years. The observation period lasted from 6 months to 2 years. Full therapeutic remission at achieved in 68,3% of patients, the number of clinic syndromes decreased by over 20,2%. Side effects were no noted.